The global oligonucleotide synthesis market size is expected to reach USD 10.17 billion by 2032, exhibiting the CAGR of 12.55% during the forecast period.
Oligonucleotide synthesis refers to the chemical process of producing short strands of nucleic acids, typically composed of 20-200 nucleotide units, which are crucial for a variety of applications in molecular biology and genetics. These synthesized oligonucleotides are used in numerous fields, including research, diagnostics, and therapeutics, particularly in gene synthesis, molecular probes, and RNA interference. As advancements in genomics, personalized medicine, and biotechnology accelerate, the demand for oligonucleotides has significantly increased.
Market’s Growth Drivers
- Advancements in Genomics and Biotechnology:
- The explosion of genomics research, particularly in areas such as next-generation sequencing (NGS), gene editing (CRISPR), and synthetic biology, has been a key driver of the oligonucleotide synthesis market. Researchers require oligonucleotides for applications such as PCR amplification, sequencing, and gene synthesis, fueling market demand.
- Rise of Personalized Medicine:
- Personalized medicine, which tailors treatments based on individual genetic profiles, is accelerating the demand for oligonucleotides. They are crucial in therapies like RNA interference (RNAi) and gene therapies, where precise genetic targeting is required to treat conditions at the molecular level.
- Growth in Biopharmaceutical R&D:
- Biopharmaceutical companies are increasingly relying on oligonucleotides for the development of innovative drugs, especially in gene therapies and nucleic acid-based therapeutics. The growing interest in RNA therapeutics, such as mRNA vaccines and antisense oligonucleotides, is further propelling market growth.
Download Free Sample PDF Copy of the Report:
Some of the major players operating in the global market include:
- Agilent Technologies
- ATDBio Ltd.
- Bio-Synthesis Inc.
- Biosearch Technologies
- Eurofins Genomics
- GE Healthcare
- Genewiz
- GenScript Corporation
- Integrated DNA Technologies (IDT)
Key Trends in the Market
- Emerging RNA-based Therapies:
- RNA-based therapeutics, including mRNA vaccines, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA) therapeutics, are gaining significant traction. This trend is driving the demand for oligonucleotides in therapeutic applications, as these molecules are essential for gene silencing, modulation, and targeted gene editing.
- Automation and High-throughput Systems:
- Automation in oligonucleotide synthesis is one of the key trends in the market. High-throughput synthesis platforms are helping to reduce production costs, enhance scalability, and improve the consistency of oligonucleotide batches. These automated systems are increasingly adopted by researchers and pharmaceutical companies, improving the efficiency of large-scale oligonucleotide production.
- Integration of AI and Machine Learning:
- Artificial intelligence (AI) and machine learning are being integrated into the oligonucleotide synthesis process to optimize synthesis conditions, predict molecule behavior, and enhance product quality. AI-driven platforms can help design oligonucleotides with improved efficiency, reduce errors, and minimize time-consuming trial and error during the synthesis process.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Oligonucleotide Synthesis, Product Outlook (Revenue – USD Billion, 2019 – 2032)
- Synthesized Oligonucleotide Products
- Equipment
- Reagents
- Services
Oligonucleotide Synthesis, Application Outlook (Revenue – USD Billion, 2019 – 2032)
- PCR Assays and Panels
- PCR Primers
- DNA Microarrays
- Sequencing
- Antisense Oligonucleotides
- Fluorescence In Situ Hybridization (FISH)
- Others
Recent Developments
- In May 2023, GenScript Biotech Corporation, a global leader in life-science research tools and services, extended its main manufacturing facility dedicated to oligonucleotide and peptide production in Zhenjiang, Jiangsu, China. This expansion reinforced GenScript’s commitment to assisting scientists globally by delivering top-notch oligos and peptides, a legacy upheld for two decades.
- In February 2023, Fluor Corporation collaborated with Agilent Technologies, Inc. for the expansion of an oligonucleotide therapeutics manufacturing facility in Colorado. The facility is designed to provide purification, synthesis, and lyophilization of nucleic acids therapeutics.
The Oligonucleotide Synthesis Market is poised for substantial growth, driven by advancements in genomics, the rise of personalized medicine, and innovations in RNA-based therapies. With increasing demand for oligonucleotides in research, diagnostics, and therapeutics, the market is expected to expand significantly. Ongoing research into synthesis technologies and the development of novel applications will continue to drive the growth of this market, making it a crucial component of the biotechnology and healthcare industries in the coming years.